Christopher Isaak - Centene Corp President
| CNC Stock | USD 60.00 0.07 0.12% |
President
Mr. Christopher R. Isaak is Senior Vice President, Corporationrationrate Controller and Chief Accounting Officer of the Company. Prior to joining Centene, he served as Vice President, Corporationrationrate Controller at TTM Technologies from 2015 to 2016 and Vice President, Corporationrationrate Controller at Viasystems Group, Inc. from 2006 to 2015 and served as Chief Accounting Officer from 2010 to 2015. since 2016.
| Age | 53 |
| Tenure | 8 years |
| Address | Centene Plaza, Saint Louis, MO, United States, 63105 |
| Phone | 314 725 4477 |
| Web | https://www.centene.com |
Centene Corp Management Efficiency
The company has Return on Asset of 0.0351 % which means that on every $100 spent on assets, it made $0.0351 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1156 %, implying that it generated $0.1156 on every 100 dollars invested. Centene Corp's management efficiency ratios could be used to measure how well Centene Corp manages its routine affairs as well as how well it operates its assets and liabilities. At present, Centene Corp's Return On Assets are projected to increase slightly based on the last few years of reporting. At present, Centene Corp's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 1.6 B, whereas Net Tangible Assets are projected to grow to (1.4 B).Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Eric Palmer | Cigna Corp | 48 | |
| Nicole Jones | Cigna Corp | 53 | |
| Kristen Lauria | Cigna Corp | 51 | |
| Jonathan Roberts | CVS Health Corp | 65 | |
| Joshua Flum | CVS Health Corp | 50 | |
| James Woys | Molina Healthcare | 65 | |
| MICHAEL TRIPLETT | Cigna Corp | 59 | |
| Meghan Joyce | Oscar Health | 36 | |
| Matt Perlberg | Cigna Corp | N/A | |
| Scott Towers | Elevance Health | N/A | |
| Mark Boxer | Cigna Corp | 59 | |
| Prem Shah | CVS Health Corp | 41 | |
| Susan Diamond | Humana Inc | 50 | |
| Alan Wheatley | Humana Inc | 51 | |
| Marianne Short | UnitedHealth Group Incorporated | 68 | |
| Cynthia Zipperle | Humana Inc | 58 | |
| Michelle Peluso | CVS Health Corp | 52 | |
| Mark Keim | Molina Healthcare | 59 | |
| Jason Sadler | Cigna Corp | 55 | |
| Noelle Eder | Cigna Corp | 54 | |
| James Clark | CVS Health Corp | 59 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0351 |
Centene Corp Leadership Team
Elected by the shareholders, the Centene Corp's board of directors comprises two types of representatives: Centene Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Centene. The board's role is to monitor Centene Corp's management team and ensure that shareholders' interests are well served. Centene Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Centene Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rich Fisher, Senior Vice President, Medicare Chief Executive Officer | ||
| Brent Layton, Executive Vice President, President - Health plans, Products, and International | ||
| Colin Toney, Executive Vice President - Mergers and Acquisitions | ||
| H Dallas, Acting Chairman of the Board, Lead Independent Director | ||
| Michael Neidorff, Chairman of the Board, President, Chief Executive Officer | ||
| Richard Gephardt, Independent Director | ||
| Katie Casso, Senior Vice President, Corporate Controller and Chief Accounting Officer | ||
| Leslie Norwalk, Independent Director | ||
| Jim Murray, Chief Transformation Officer | ||
| Kenneth Fasola, President | ||
| Jeffrey Schwaneke, Senior Vice President Chief Accounting Officer, Corporate Controller | ||
| David Steward, Independent Director | ||
| Christopher Koster, Executive Vice President, General Counsel, Company Secretary | ||
| Lori Robinson, Independent Director | ||
| Suzy DePrizio, Senior Vice President Chief Marketing Officer | ||
| Shannon Susko, Senior Officer | ||
| Thomas Thompson, Independent Director | ||
| Jesse Hunter, Executive Vice President - Mergers and Acquisitions, Chief Strategy Officer | ||
| Robert Ditmore, Presiding Independent Director | ||
| William Trubeck, Independent Director | ||
| Jonathan Dinesman, Executive Vice President - Government Relations | ||
| Mark Brooks, Executive Vice President, Chief Information Officer | ||
| Kenneth Burdick, Executive Vice President - Markets & Products | ||
| Robert Sanders, Executive Resources | ||
| Christopher Coughlin, Independent Director | ||
| Jennifer Gilligan, Senior Vice President of Investor Relations | ||
| Frederick Eppinger, Independent Director | ||
| H Sanders, Executive Vice President - Global Human Resources | ||
| Theodore Samuels, Independent Director | ||
| Sarah London, President - Health Care Enterprises and Executive Vice President - Advanced Technology | ||
| Brandy Burkhalter, Chief Operating Officer, Executive Vice President | ||
| Orlando Ayala, Independent Director | ||
| Jessica Blume, Independent Director | ||
| Brian MBA, Chief Officer | ||
| Keith Williamson, Executive Vice President General Counsel, Secretary | ||
| Shannon Bagley, Executive Vice President, Chief Administrative Officer | ||
| Wayne DeVeydt, Independent Director | ||
| Tommy Thompson, Independent Director | ||
| Christopher Isaak, Senior Vice President Corporate Controller and Chief Accounting Officer | ||
| Susan Smith, Chief Officer | ||
| David Thomas, Executive Vice President - Marketing | ||
| John Roberts, Independent Director | ||
| Andrew Asher, Chief Financial Officer, Executive Vice President | ||
| Ashlee Knuckey, Chief Officer |
Centene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Centene Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0351 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 30.29 B | ||||
| Shares Outstanding | 504.86 M | ||||
| Shares Owned By Insiders | 0.27 % | ||||
| Shares Owned By Institutions | 99.45 % | ||||
| Number Of Shares Shorted | 15.16 M | ||||
| Price To Earning | 20.27 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Centene Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Centene Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Centene Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Centene Corp Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centene Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Centene Stock refer to our How to Trade Centene Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centene Corp. If investors know Centene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centene Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.565 | Earnings Share 5.79 | Revenue Per Share 275.741 | Quarterly Revenue Growth 0.061 | Return On Assets 0.0351 |
The market value of Centene Corp is measured differently than its book value, which is the value of Centene that is recorded on the company's balance sheet. Investors also form their own opinion of Centene Corp's value that differs from its market value or its book value, called intrinsic value, which is Centene Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centene Corp's market value can be influenced by many factors that don't directly affect Centene Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centene Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Centene Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centene Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.